Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors

1 junio 2015

A metabolite of an FDA-approved drug for metastatic prostate cancer, abiraterone, has more anti-cancer properties than its precursor, researchers have discovered for the first time. Prostate cancer is the most common cancer in men, with nearly 240,000 new cases diagnosed each year in the United State.